TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
PLAINSBORO, N.J., May 03, 2017 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it will present at the following conferences in May:
- At 10:40AM PT on Tuesday, May 16, 2017, Mr. Glenn Coleman, chief financial officer and corporate vice-president of International, will present at the Bank of America Merrill Lynch 2017 Global Healthcare Conference in Las Vegas, NV. This presentation will be webcast.
- At 9:30AM ET on Monday, May 22, 2017, Mr. Dan Reuvers, president of Specialty Surgical Solutions, will present at the UBS 2017 Global Healthcare Conference in New York City. This presentation will not be webcast.
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Nora Brennan (609) 936-2488 [email protected] Michael Beaulieu (609) 750-2827 [email protected]
